Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
15,733
datasets available to search
ShareScore release 0.9.0
Dataset results
15,733 results for “article”
Dataset related to article: " ENTROPY METRICS CORRELATING WITH HIGHER RESIDUAL FUNCTIONING IN PATIENTS WITH CHRONIC DISORDERS OF CONSCIOUSNESS "
<p>the dataset contains data ENTROPY MEASURES</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p>
dataset related to submitted article "Novel HSPG2 gene mutation causing Schwartz-Jampel syndrome in a Moroccan family and review of the literature"
<p>Next Generation Sequencing, real-time, sequensing cDNA</p>
Datasets and Codes related to article "Association between duration of SARS-CoV-2 positivity and long COVID "
<p>This record contains raw data related to article “Association between duration of SARS-CoV-2 positivity and long COVID "</p> <p> </p> <p>In an observational study, we analyzed 1,293 healthcare workers previously infected with SARS-CoV-2, of which 34.1% developed long COVID. Using a multivariate logistic regression model, we demonstrate that the likelihood of developing long COVID in infected individuals rises with the increasing of duration of infection and that three doses of the BNT162b2 vaccine are protective, even during the Omicron wave.</p> <p>In this observational study, approved by the Institutional Review Board of Humanitas Research Hospital, we recruited 4,354 individuals working in Humanitas healthcare facilities from March 2020 to April 2022. they completed a survey including demographics, comorbidities, vaccination status and questions about their SARS-CoV-2 history: date of infection and positivity duration; SARS-CoV-2 related symptoms at the time of infection and their duration. We defined ‘long COVID’ as the condition when at least one symptom lasted for more than 4 weeks following the first COVID-19 infection.</p>
Dataset for the article "Phenotypic correlates of serum neurofilament light chain levels in amyotrophic lateral sclerosis" (Verde et al., Front Aging Neurosci 2023)
<p>This is the dataset of the study "Phenotypic correlates of serum neurofilament light chain levels in amyotrophic lateral sclerosis" (Verde et al., Front Aging Neurosci 2023).</p>
Supplementary Data for an under-reviewing article.
<p>Supplementary Data for the under-reviewing article "Phylogenetic evidence reveals early Kra-Dai divergence and dispersal in the late Holocene".</p> <p>Supplementary Data 1: The lexical cognate database of Kra-Dai languages. Sheet 1 “Lexical items” shows the language entries and lexical items of 100 Kra-Dai languages. Sheet 2 “Binary coded sets” shows the binary coded form based on Sheet 1. Sheet 3 “Note” shows the reason for deleting specific lexical items and descriptions for the data. Supplementary Data 2: Node constraints with known historical information used to calibrate the divergence time calculations in BEAST. Supplementary Data 3: Model comparison among different combinations of models in BEAST. Sheet 1 “HME” shows the results compared by Harmonic Mean Estimator. Sheet 2 “Path Sampling” shows the results compared by the path sampling method. Supplementary Data 4: Possibilities of ancestral area. Supplementary Data 5: Comparison of time depth and root probability among versions of different settings. Supplementary Data 6: Delta score and Q-residual. Supplementary Data 7: Information on archaeological sites in South China and MSEA. Supplementary Data 8: Resources of linguistic data. Supplementary Data 9: BEAST xml files, nexus files, MCC tree file, and log file. Supplementary Data 10: Statistical significance among models of dispersal routes in the posterior samples of 3 independent runs of the RJMCMC. Supplementary Data 11: The control file, input file, and geographical distribution file used in the <em>BayesTraits</em> program. 3 MCMC run log files were also included. Supplementary Data 12: Kra-Dai population samples used for BSP analysis. Supplementary Data 13: The interdisciplinary data and code used to plot Figure 3.</p>
Dataset related to article "Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I"
<p>This record contains raw data (metabolomic and RNASeq data) related to the article: "Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I"</p>
Dataset relateted to article " PROVA"
<p>Dataset supporting results of article described at title [prova]</p>
Dataset related to article "Reduced G protein signaling despite impaired internalization and β-arrestin recruitment in patients carrying a novel CXCR4Leu317fsX3 mutation causing WHIM syndrome"
<p>This record contains raw data related to article "IReduced G protein signaling despite impaired internalization and β-arrestin recruitment in patients carrying a novel CXCR4Leu317fsX3 mutation causing WHIM syndrome"</p><p>WHIM syndrome is an inherited immune disorder caused by an autosomal dominant heterozygous mutation in CXCR4.<i> </i>The disease is characterized by neutropenia/leukopenia (secondary to retention of mature neutrophils in bone marrow), recurrent bacterial infections, treatment-refractory warts, and hypogammaglobulinemia. All mutations reported in WHIM patients lead to the truncations in the C-terminal domain of CXCR4, R334X being the most frequent. This defect prevents receptor internalization, and enhances both calcium mobilization and ERK phosphorylation, resulting in increased chemotaxis in response to the unique ligand CXCL12. Here, we describe three patients presenting neutropenia and myelokathexis, but normal lymphocyte count and immunoglobulin levels, carrying a novel Leu317fsX3 mutation in CXCR4, leading to a complete truncation of its intracellular tail. The analysis of the L317fsX3 mutation in cells derived from patients and <i>in vitro</i> cellular models reveals unique signaling features when compared to R334X mutation. L317fsX3 mutation impairs CXCR4 downregulation and β-arrestin recruitment in response to CXCL12 and reduces other signaling events including ERK1/2 phosphorylation, calcium mobilization and chemotaxis, all processes, which are typically enhanced in cells carrying the R334X mutation. Our findings suggest that overall, the L317fsX3 mutation may be causative of a form of WHIM syndrome not associated with an augmented CXCR4 response to CXCL12.</p>
Dataset related to article "Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors"
<p>This record contains raw data related to article "Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors"</p><p>Abstract</p><p><strong>Objective: </strong>The aim of this study was to evaluate clinical results and prognostic factors in a cohort of patient with oligometastatic esophagogastric adenocarcinoma treated with stereotactic radiation therapy (SRT).</p><p><strong>Methods: </strong>This retrospective study included patients affected by 1-3 metastases treated with SRT from 2013 to 2021. Local control (LC), overall survival (OS), progression-free survival (PFS), time to polymetastatic dissemination (TTPD) and time to systemic therapy change/initiation (TTS) were evaluated.</p><p><strong>Results: </strong>Between 2013 and 2021, 55 patients were treated with SRT on 80 oligometastatic sites. Median follow-up was 20 months. Nine patients had local progression. 1 and 3 years LC was respectively 92 and 78%. 41 patients experienced further distant disease progression, median PFS was 9.6 months, 1 and 3 years PFS was respectively 40 and 15%. 34 patients died, median OS was 26.6 months, 1 and 3 years OS was respectively 78 and 40%. During follow-up, 24 patients changed or initiated a new systemic therapy; median TTS time was 9 months. 27 patients experienced poliprogression, 44% after 1 year and 52% after 3 years. Median TTPD was 8 months. The best local response (LR), tyming of metastases and PS were related with prolonged PFS on multivariate analysis. LR was correlated with OS at multivariate analysis.</p><p><strong>Conclusion: </strong>SRT represents a valid treatment for oligometastatic esophagogastric adenocarcinoma. CR correlated with PFS and OS, while metachronous metastasis and a good PS correlated with a better PFS.</p><p><strong>Advances in knowledge: </strong>In selected gastroesopagheal oligometastatic patients, SRT can prolong OS Local response to SRT, metachronous timing of metastases and better PS improve PFS.Local response correlates with OS</p>
Dataset related to article "Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study"
<p>This record contains raw data related to article "Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study"</p><p>Abstract</p><p><strong>Purpose: </strong>The lung is the most frequent site of metastasis in patients with sarcoma. Pulmonary metastasectomy is the most common treatment performed. Stereotactic body radiation therapy (SBRT) has proven to be a potential alternative to resection. This prospective phase 2 study aimed to assess the role of SBRT for patients with lung metastases.</p><p><strong>Methods and materials: </strong>Adult patients with up to 4 lung metastases (LMs) ≤5 cm in diameter and unsuitable for surgery were included. Dose prescription was based on site and size: 30 Gy/1 fraction for peripheral lesions ≤10 mm, 60 Gy/3 fractions for peripheral lesions 11 to 20 mm, 48 Gy/4 fractions for peripheral lesions >20 mm, and 60 Gy/8 fractions for central lesions. The primary endpoint was the proportion of treated lesions free from progression at 12 months. Secondary endpoints were disease-free survival (DFS), overall survival (OS), and toxicity.</p><p><strong>Results: </strong>Between March 2015 and December 2020, 44 patients with a total of 71 LMs were enrolled. Twelve-month local control was 98.5% ± 1.4%, reaching the primary aim; the median DFS time was 12 months (95% CI, 8-16 months), and the 1-, 2-, 3-, 4-, and 5-year PFS rates were 50% ± 7.5%, 19.5% ± 6.6%, 11.7% ± 5.8%, 11.7% ± 5.8%, and 11.7% ± 5.8%, respectively. The median OS time was 49 months (95% CI, 24-49 months), and the 1-, 2-, 3-, 4-, and 5-year OS rates were 88.6% ± 4.7%, 66.7 ± 7.6%, 56.8% ± 8.4%, 53.0% ± 8.6%, and 48.2% ± 9.1%, respectively. Prognostic factors recorded as significantly affecting survival were age, grade of primary sarcoma, interval time from diagnosis to occurrence of LMs, and number of LMs. No severe pulmonary toxicity (grade 3-4) occurred.</p><p><strong>Conclusions: </strong>The study found a local control of LMs in almost all patients treated, with negligible toxicity. Survival was also highly satisfactory. Well-designed randomized trials comparing surgery with SBRT for patients with metastatic lung sarcoma are needed to confirm these preliminary data</p>
doi_________::001320efbdc8ffdfcc92cb1fc7f4f779
Open the record for dataset details and reuse information.
doi_________::001534b70812ed48cfde03c0562e155a
Open the record for dataset details and reuse information.
doi_________::0016144222bab21850033ebd95cb231e
Open the record for dataset details and reuse information.
doi_________::001880a669a26dd5300930a3a4f08b7d
Open the record for dataset details and reuse information.
doi_________::001bf7599fb89d23d73823ed56e774b9
Open the record for dataset details and reuse information.
doi_________::001c2c4feffcad00289d038245aa0586
Open the record for dataset details and reuse information.
doi_________::001ee3a163ff0adb532c80d43544f502
Open the record for dataset details and reuse information.
doi_________::0024b87dd03854c47d2c1e29641828c1
Open the record for dataset details and reuse information.
doi_________::003f865de3c07634fdc849a377fdc273
Open the record for dataset details and reuse information.
doi_________::0047059d626cea345641f3b6bf6a7949
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.